Loading…
← CockpitCompetitor Analysis › GUFICBIO.NS Gufic Biosciences LimitedOpen in the cockpit ↗

Gufic Biosciences LimitedGUFICBIO.NSCompetitor analysis, valuation and peers

India · INR·Pharma & Healthcare›Pharmaceuticals: Major
Momentum leader 85
Mkt cap
$452M
US dollars, full cap
Free float
22%
of shares outstanding
$/day
$798,379
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
+4.4 pp
WACC 10.7%
Hurdle
n/a
no reverse DCF
Close · INR₹422.25
1D-4.0%
1W-9.7%
1M+4.4%
3M+0.2%
6M+47.6%
YTD+25.7%
1Y+27.7%
ATR %5.4%
Beta0.64
52w lowhigh14.5% off high

What Gufic Biosciences does

Employees: 2,903

Gufic Biosciences at a glance

Size Gufic Biosciences (GUFICBIO.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $452M, the 893rd largest of 1,066 India companies the cockpit tracks. Shares closed at ₹422.25 on 18 Nov 2026.

Performance Over six months the shares gained 47.6%, against -21.2% for the median peer and +3.8% for the India market (cap-weighted) — 2nd highest of 20 in its peer set.

Growth Revenue grew 16.7% over the last twelve months (peer median +4.9%); the operating margin is 13.6% (peer median 4.3%).

Valuation It trades at 4.3× enterprise value to sales against a peer median of 3.4× (8th most expensive of 19).

Capital Return on invested capital runs 4.4 points above its cost of capital (10.7% WACC).

Relative performance

10015021 May 202621 Aug 202618 Nov 2026GUFICBIO.NS 148Peer median 80
Six months, rebased to 100: Gufic Biosciences against the median of its 20 peers (local-currency closes).

Gufic Biosciences financials

Reported figures in INR; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₹9.81B₹9.44B₹8.20B₹8.07B₹6.91B
Revenue growth—+15%+2%+17%—
Gross profit₹3.57B₹2.59B₹2.44B₹2.41B₹2.05B
EBITDA₹1.65B₹1.54B₹1.40B₹1.50B₹1.40B
Net income₹735M₹642M₹696M₹861M₹797M
Free cash flown/a-₹178M₹271M-₹1.32B-₹2.20B
Capital expendituren/a₹312M₹755M₹1.13B₹1.88B
Total debtn/a₹4.05B₹3.36B₹3.33B₹3.34B

Quarterly statements and history in the cockpit →

Gufic Biosciences competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%-20%0%+20%603566000640603811ASMBRPGLIFE002462002693000518KPLCAPREOLS6620688136605077688117301201GUFICBIO.NS6-month return →1-month return →
Up and to the right = strong over both horizons. Gufic Biosciences is the large dot.

Fundamentals: revenue growth against valuation

-50%0%+50%0×5×10×15×603566000640603811ASMBRPGLIFE002462002693002900000788000518KPL002370EOLS6620688136605077688117301201GUFICBIO.NSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Gufic Biosciences is the large dot.

Gufic Biosciences competitors and peer comparison

How Gufic Biosciences compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Gufic Biosciences against its 20 peers (data as of 18 Nov 2026)
MeasureGUFICBIO.NSPeer medianRank in peer set
1-month return+4.4%-11.0%4th highest of 21
6-month return+47.6%-21.2%2nd highest of 20
Distance from 52-week high-14.5%-41.2%2nd highest of 21
Revenue growth (TTM)+16.7%+4.9%7th highest of 20
Operating margin13.6%4.3%6th highest of 19
EV / Sales4.3×3.4×8th most expensive of 19
ROIC minus cost of capital+4.4 pp-2.2 pp5th highest of 19
EV / EBITDA25.6×25.9×2nd cheapest of 4
Net debt / EBITDA2.0×0.9×2nd most indebted of 4

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Gufic Biosciences GUFICBIO.NSIndia$452M+48%+17%14%4.3×n/an/a
Pulike Biological Engineering 603566.SSChina$449M-21%-9%5%2.4×4.5%+3.3%
Dong-A Socio 000640.KSSouth Korea$447M-8%+11%7%0.7×-6.6%+12.8%
Zhejiang Chengyi Pharmaceutical 603811.SSChina$445M-21%+5%19%3.4×1.3%+1.3%
Assembly Biosciences ASMBUnited States$458M-15%+80%-32%2.2×n/an/a
RPG Life Sciences RPGLIFE.NSIndia$443M+10%+15%17%5.3×n/an/a
Cachet Pharmaceutical 002462.SZChina$441M-25%-14%0%0.2×-9.9%-3.4%
BlossomHill Therapeutics BLSMUnited States$464Mn/an/an/an/an/an/a
Hainan Shuangcheng Pharmaceuticals 002693.SZChina$465M-28%+40%13%10.8×44.1%+1.0%
Harbin Medisan Pharmaceutical 002900.SZChina$437M-16%-5%-29%4.2×n/an/a
PKU Healthcare 000788.SZChina$437M-12%-49%5%2.1×-5.6%-5.6%
Jiangsu Sihuan Bioengineering 000518.SZChina$437M-8%-17%-28%10.6×n/an/a
Kwality Pharmaceuticals KPL.NSIndia$467M+110%+48%22%7.2×n/an/a
Capricor Therapeutics CAPRUnited States$467M-70%-100%n/an/an/an/a
Zhejiang Yatai Pharmaceutical 002370.SZChina$468M-32%-4%-11%8.8×n/an/a
Evolus EOLSUnited States$468M+7%+14%-5%1.8×n/an/a
Handa Pharmaceuticals 6620.TWOTaiwan$469M+45%-16%30%16.6×24.8%+126.7%
Kexing Biopharm 688136.SSChina$433M-42%-14%-12%2.9×n/an/a
Zhejiang Huakang Pharmaceutical 605077.SSChina$433M-47%+35%4%1.1×n/an/a
Cheng Du Sheng Nuo Biotec 688117.SSChina$433M-48%+51%27%3.4×-0.2%+14.5%
ChengDa PharmaCeuticals 301201.SZChina$472M-47%+27%-9%4.8×n/an/a

Questions

Which companies are Gufic Biosciences's closest peers?
The cockpit's peer set: Pulike Biological Engineering (603566.SS), Dong-A Socio (000640.KS), Zhejiang Chengyi Pharmaceutical (603811.SS), Assembly Biosciences (ASMB), RPG Life Sciences (RPGLIFE.NS), Cachet Pharmaceutical (002462.SZ), BlossomHill Therapeutics (BLSM), Hainan Shuangcheng Pharmaceuticals (002693.SZ).
Is Gufic Biosciences expensive compared with its peers?
On ev / sales it trades at 4.3× against a peer median of 3.4×, 8th most expensive of 19 in its peer set.
How has Gufic Biosciences stock performed?
Over six months to 18 Nov 2026 the shares returned +47.6% against -21.2% for the median peer; over one year +27.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.